Data / Drug companies / Patheon Italia S.p.A.
Patheon Italia S.p.A.: 101 products in the FDA NDC directory, labeler code 68225
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patheon Italia S.p.A. (labeler code 68225) lists 101 products in the FDA National Drug Code Directory. By type: 99 drugs for further processing, 1 bulk ingredients. Its main marketing category is drugs for further processing. The newest product started marketing on September 4, 2026.
The request: Watch Patheon Italia S.p.A. (FDA labeler code 68225): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68225
- Products in commercial distribution
- 101
- Packages
- 112
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 1, Schedule V 1
- Started marketing in the last 12 months
- 25
- Earliest marketing start
- December 31, 1985
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 101 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 99 | 98% |
| Bulk ingredients | 1 | 1% |
| Licensed vaccine bulk intermediate | 1 | 1% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 41 | 40.6% |
| Injection, solution | 22 | 21.8% |
| Powder, for solution | 12 | 11.9% |
| Injection | 11 | 10.9% |
| Solution | 4 | 4% |
| Injection, solution, concentrate | 3 | 3% |
| Powder | 3 | 3% |
| Injection, powder, for solution | 2 | 2% |
| Injection, suspension | 1 | 1% |
| Patch | 1 | 1% |
| Kit | 1 | 1% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zilganersen | 68225-282 | Injection, solution, concentrate | Drugs for further processing | September 4, 2026 |
| Teduglutide | 68225-265 | Injection, powder, lyophilized, for solution | Drugs for further processing | September 2, 2026 |
| Rusfertide | 68225-270 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 28, 2026 |
| Rusfertide | 68225-269 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 28, 2026 |
| Rusfertide | 68225-268 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 28, 2026 |
| Rusfertide | 68225-267 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 28, 2026 |
| Rusfertide | 68225-266 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 28, 2026 |
| Evolocumab | 68225-262 | Injection, solution | Drugs for further processing | June 3, 2026 |
| Emapalumab-lzsg | 68225-287 | Injection | Drugs for further processing | January 1, 2026 |
| Emapalumab-lzsg | 68225-286 | Injection | Drugs for further processing | January 1, 2026 |
| Emapalumab-lzsg | 68225-285 | Injection | Drugs for further processing | January 1, 2026 |
| Ustekinumab-ttwe | 68225-284 | Injection, solution | Drugs for further processing | January 1, 2026 |
| Velmanase alfa-tycv | 68225-283 | Injection, powder, lyophilized, for solution | Drugs for further processing | January 1, 2026 |
| Somatropin | 68225-281 | Injection, powder, lyophilized, for solution | Drugs for further processing | January 1, 2026 |
| Aflibercept | 68225-280 | Injection | Drugs for further processing | January 1, 2026 |
| Aflibercept-mrbb | 68225-279 | Injection, solution | Drugs for further processing | January 1, 2026 |
| Fibrinogen human and human thrombin | 68225-278 | Patch | Drugs for further processing | January 1, 2026 |
| Asfotase alfa | 68225-277 | Solution | Drugs for further processing | January 1, 2026 |
| Asfotase alfa | 68225-276 | Solution | Drugs for further processing | January 1, 2026 |
| Asfotase alfa | 68225-275 | Solution | Drugs for further processing | January 1, 2026 |
| Asfotase alfa | 68225-274 | Solution | Drugs for further processing | January 1, 2026 |
| Ustekinumab-stba | 68225-273 | Injection, solution | Drugs for further processing | January 1, 2026 |
| Ustekinumab-stba | 68225-272 | Injection, solution | Drugs for further processing | January 1, 2026 |
| Denosumab-bmwo | 68225-271 | Injection | Drugs for further processing | January 1, 2026 |
| Teprotumumab | 68225-264 | Injection, powder, lyophilized, for solution | Drugs for further processing | January 1, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.